OVID - Ovid Therapeutics Inc.

QQQ $ 479.35 $ 5.42 (1.14 %)

DIA $ 391.06 $ -2.96 (-0.75 %)

SPY $ 544.78 $ 2.09 (0.39 %)

TLT $ 94.49 $ 0.16 (0.17 %)

GLD $ 214.55 $ -1.07 (-0.5 %)

Previous Close

$ 0.7

Open

$ 0.77

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 0.69 - $ 0.77

52 Week Range

$ 0.69 - $ 4.14

Volume

3,210,150

Average Volume

Market Cap

49.5M

Beta (5Y Monthly)

$ 0.81

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-14-2024	03-31-2024	10-Q
2	03-08-2024	12-31-2023	10-K
3	11-03-2023	09-30-2023	10-Q
4	08-04-2023	06-30-2023	10-Q
5	05-05-2023	03-31-2023	10-Q
6	03-13-2023	12-31-2022	10-K
7	11-08-2022	09-30-2022	10-Q
8	08-09-2022	06-30-2022	10-Q
9	05-10-2022	03-31-2022	10-Q
10	03-15-2022	12-31-2021	10-K
11	11-10-2021	09-30-2021	10-Q
12	08-16-2021	06-30-2021	10-Q
13	05-13-2021	03-31-2021	10-Q
14	03-15-2021	12-31-2020	10-K
15	11-13-2020	09-30-2020	10-Q
16	08-10-2020	06-30-2020	10-Q
17	05-07-2020	03-31-2020	10-Q
18	03-11-2020	12-31-2019	10-K
19	11-08-2019	09-30-2019	10-Q
20	08-07-2019	06-30-2019	10-Q
21	05-07-2019	03-31-2019	10-Q
22	03-07-2019	12-31-2018	10-K
23	11-08-2018	09-30-2018	10-Q
24	08-09-2018	06-30-2018	10-Q
25	05-08-2018	03-31-2018	10-Q
26	03-29-2018	12-31-2017	10-K
27	11-09-2017	09-30-2017	10-Q
28	08-10-2017	06-30-2017	10-Q
29	06-13-2017	03-31-2017	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

BTIG Maintains Buy on Ovid Therapeutics, L...
06/18/2024 16:56:29

BTIG analyst Thomas Shrader maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and lowers the price target from $11 to $5.

B. Riley Securities Maintains Buy on Ovid ...
06/18/2024 15:10:44

B. Riley Securities analyst Kalpit Patel maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and lowers the price target fr...

Citigroup Maintains Neutral on Ovid Therap...
06/18/2024 14:44:28

Citigroup analyst Yigal Nochomovitz maintains Ovid Therapeutics (NASDAQ:OVID) with a Neutral and lowers the price target fro...

Evaluating Ovid Therapeutics: Insights Fro...
06/18/2024 13:00:43

HC Wainwright & Co. Maintains Buy on Ovid ...
06/18/2024 12:20:01

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Ovid Therapeutics (NASDAQ:OVID) with a Buy and lowers the price...

nasdaq-surges-over-200-points-aarons-shares-jump

Nasdaq Surges Over 200 Points; Aaron's Sha...
06/17/2024 18:40:51

why-ovid-therapeutics-shares-are-trading-lower-by-19-here-are-other-stocks-moving-in-mondays-mid-day-session

Why Ovid Therapeutics Shares Are Trading L...
06/17/2024 17:21:47

12-health-care-stocks-moving-in-mondays-intraday-session

12 Health Care Stocks Moving In Monday's I...
06/17/2024 16:31:43

Crude Oil Rises 1%; Mustang Bio Shares Spi...
06/17/2024 16:16:09

US Stocks Mixed; Dow Tumbles Over 100 Points
06/17/2024 13:40:41

whats-going-on-with-ovid-therapeutics-after-takedas-two-phase-3-epilepsy-studies-fail

What's Going On With Ovid Therapeutics Aft...
06/17/2024 12:58:59

Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In ...

why-nurix-therapeutics-shares-are-trading-higher-by-around-12-here-are-20-stocks-moving-premarket

Why Nurix Therapeutics Shares Are Trading ...
06/17/2024 12:43:16

12-health-care-stocks-moving-in-mondays-pre-market-session

12 Health Care Stocks Moving In Monday's P...
06/17/2024 12:07:49

After Takeda's Phase 3 Topline Study Resul...
06/17/2024 11:01:02

Takeda Announced Topline Data From SKYLINE...
06/17/2024 10:48:35

SKYLINE Study in Dravet Syndrome Narrowly Missed its Primary Endpoint of Reduction in Convulsive Seizure Frequency and Showed ...

HC Wainwright & Co. Reiterates Buy on Ovid...
05/16/2024 11:07:06

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ovid Therapeutics (NASDAQ:OVID) with a Buy and maintains $9 pr...

Ovid Therapeutics Q1 EPS $(0.17) Beats $(0...
05/14/2024 12:19:53

Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0...

Cracking The Code: Understanding Analyst R...
05/07/2024 19:00:38

Citigroup Maintains Neutral on Ovid Therap...
05/07/2024 17:42:09

Citigroup analyst Yigal Nochomovitz maintains Ovid Therapeutics (NASDAQ:OVID) with a Neutral and lowers the price target fro...

B. Riley Securities Initiates Coverage On ...
04/30/2024 12:34:48

B. Riley Securities analyst Kalpit Patel initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Buy rating and announc...